Literature DB >> 17607578

Inherited factor XI deficiency: a concise review.

Massimo Franchini1, Dino Veneri, Giuseppe Lippi.   

Abstract

Inherited factor XI (FXI) deficiency, also called Hemophilia C, is an uncommon autosomal recessive disorder, which is associated with a variable bleeding tendency that usually manifests after trauma or surgery. This concise report reviews current knowledge regarding the pathogenesis, genetics, diagnosis, clinical manifestations and management of this inherited bleeding disorder.

Entities:  

Mesh：

Year:  2006        PMID： 17607578     DOI： 10.1080/10245330600921964

Source DB:  PubMed          Journal:  Hematology        ISSN： 1024-5332            Impact factor:   2.269


  7 in total

1.  Discovery of a Potent Parenterally Administered Factor XIa Inhibitor with Hydroxyquinolin-2(1H)-one as the P2' Moiety.

Authors:  Zilun Hu; Pancras C Wong; Paul J Gilligan; Wei Han; Kumar B Pabbisetty; Jeffrey M Bozarth; Earl J Crain; Timothy Harper; Joseph M Luettgen; Joseph E Myers; Vidhyashankar Ramamurthy; Karen A Rossi; Steven Sheriff; Carol A Watson; Anzi Wei; Joanna J Zheng; Dietmar A Seiffert; Ruth R Wexler; Mimi L Quan
Journal:  ACS Med Chem Lett       Date:  2015-04-08       Impact factor: 4.345

2.  Single-Dose Pharmacokinetics of Milvexian in Participants with Mild or Moderate Hepatic Impairment Compared with Healthy Participants.

Authors:  Vidya Perera; Grigor Abelian; Danshi Li; Zhaoqing Wang; Liping Zhang; Susan Lubin; Wei Chen; Akintunde Bello; Bindu Murthy
Journal:  Clin Pharmacokinet       Date:  2022-03-09       Impact factor: 5.577

3.  Conversion Total Hip Arthroplasty Following Failed Hip Fracture Fixation in a Patient with Factor XI Deficiency: A Case Report.

Authors:  Joseph R Young; Jared Roberts
Journal:  J Orthop Case Rep       Date:  2020 May-Jun

4.  First-in-human study of milvexian, an oral, direct, small molecule factor XIa inhibitor.

Authors:  Vidya Perera; Zhaoqing Wang; Joseph Luettgen; Danshi Li; Mary DeSouza; Michael Cerra; Dietmar Seiffert
Journal:  Clin Transl Sci       Date:  2021-09-24       Impact factor: 4.689

5.  Single-Dose Pharmacokinetics of Milvexian in Participants with Normal Renal Function and Participants with Moderate or Severe Renal Impairment.

Authors:  Vidya Perera; Grigor Abelian; Danshi Li; Zhaoqing Wang; Liping Zhang; Susan Lubin; Akintunde Bello; Bindu Murthy
Journal:  Clin Pharmacokinet       Date:  2022-07-30       Impact factor: 5.577

6.  Targeting coagulation factor XII as a novel therapeutic option in brain trauma.

Authors:  Sarah Hopp; Christiane Albert-Weissenberger; Stine Mencl; Michael Bieber; Michael K Schuhmann; Christian Stetter; Bernhard Nieswandt; Peter M Schmidt; Camelia-Maria Monoranu; Irina Alafuzoff; Niklas Marklund; Marc W Nolte; Anna-Leena Sirén; Christoph Kleinschnitz
Journal:  Ann Neurol       Date:  2016-04-28       Impact factor: 10.422

7.  Safety, pharmacokinetics, and pharmacodynamics of milvexian in healthy Japanese participants.

Authors:  Vidya Perera; Zhaoqing Wang; Susan Lubin; Takayo Ueno; Tomomi Shiozaki; Wei Chen; Xiaohui Xu; Dietmar Seiffert; Mary DeSouza; Bindu Murthy
Journal:  Sci Rep       Date:  2022-03-25       Impact factor: 4.379
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.